HAVN Life Sciences Past Earnings Performance
Past criteria checks 0/6
HAVN Life Sciences has been growing earnings at an average annual rate of 28.8%, while the Biotechs industry saw earnings growing at 16.6% annually. Revenues have been growing at an average rate of 876.8% per year.
Key information
28.8%
Earnings growth rate
61.4%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 876.8% |
| Return on equity | -1,875.2% |
| Net Margin | -2,676.6% |
| Last Earnings Update | 31 Jan 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How HAVN Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 23 | 1 | -16 | 3 | 1 |
| 31 Oct 22 | 1 | -17 | 4 | 1 |
| 31 Jul 22 | 0 | -21 | 6 | 1 |
| 30 Apr 22 | 0 | -22 | 7 | 1 |
| 31 Jan 22 | 0 | -22 | 11 | 1 |
| 31 Oct 21 | 0 | -33 | 14 | 1 |
| 31 Jul 21 | 0 | -33 | 15 | 1 |
| 30 Apr 21 | 0 | -30 | 14 | 0 |
Quality Earnings: HAVN is currently unprofitable.
Growing Profit Margin: HAVN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HAVN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare HAVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HAVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: HAVN has a negative Return on Equity (-1875.22%), as it is currently unprofitable.